Clear Str Upgrades Evommune (NYSE:EVMN) to Strong-Buy

Evommune (NYSE:EVMN) was upgraded by Clear Str to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

EVMN has been the topic of several other reports. Oppenheimer began coverage on shares of Evommune in a research report on Thursday, January 22nd. They issued an “outperform” rating and a $42.00 price target on the stock. Cantor Fitzgerald began coverage on Evommune in a report on Monday, December 1st. They issued an “overweight” rating on the stock. HC Wainwright lowered their target price on Evommune from $65.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday. Morgan Stanley reaffirmed an “overweight” rating and issued a $54.00 price objective on shares of Evommune in a research note on Wednesday, February 18th. Finally, Wall Street Zen raised Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $47.17.

Evommune Price Performance

Shares of NYSE:EVMN opened at $23.32 on Tuesday. The stock has a 50-day moving average price of $23.26. The stock has a market capitalization of $839.76 million and a PE ratio of -2.89. Evommune has a 52-week low of $13.89 and a 52-week high of $33.20.

Evommune (NYSE:EVMN) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Institutional Investors Weigh In On Evommune

A number of institutional investors have recently added to or reduced their stakes in the stock. Oxford Asset Management LLP purchased a new position in shares of Evommune in the fourth quarter worth $335,000. XTX Topco Ltd purchased a new position in Evommune during the fourth quarter valued at $321,000. The Manufacturers Life Insurance Company purchased a new position in Evommune during the fourth quarter valued at $179,000. Sofinnova Investments Inc. bought a new stake in Evommune in the 4th quarter valued at $2,625,000. Finally, Eventide Asset Management LLC purchased a new stake in Evommune in the 4th quarter worth $16,461,000.

Key Stories Impacting Evommune

Here are the key news stories impacting Evommune this week:

• Positive Sentiment: Clear Street initiated coverage with a Buy recommendation, giving independent buying interest and analyst coverage that can support demand for the shares. Clear Street initiates coverage of Evommune (EVMN) with buy recommendation
• Positive Sentiment: Evommune’s Relative Strength (RS) rating rose to 91, indicating stronger price momentum versus peers — a technical positive that can attract momentum-focused buyers. Stocks to watch: Evommune sees RS rating rise to 91
• Neutral Sentiment: HC Wainwright lowered its price target from $65 to $50 but maintained a “Buy” rating — the cut reduces upside vs. prior targets but still implies substantial upside from current levels, leaving investor reaction mixed. Benzinga coverage of HC Wainwright price target change
• Negative Sentiment: HC Wainwright materially reduced near‑term and full‑year EPS forecasts: Q1 2026 to ($0.83), Q2 to ($0.71), Q3 to ($0.71), Q4 to ($0.75) and FY2026 to ($3.00) (down from prior estimates). The shop also issued a FY2027 EPS forecast of ($3.30). Those downgrades signal worsening profitability/visibility and are the primary driver of today’s weakness. HC Wainwright Issues Pessimistic Forecast for Evommune (NYSE:EVMN) Stock Price

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.